Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pardes Biosciences Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific workload is concentrated under 1 distinct examiner and 1 distinct art unit. The focus of current prosecution activity rests entirely with examiner MCDOWELL, BRIAN E, who is responsible for the 1 busiest examiner pending office action.
For a practitioner, this centralized portfolio structure means that prosecution outcomes are currently dependent on the assigned personnel at the USPTO. With 1 distinct examiner involved, the applicant lacks the diversity of examiner perspectives that larger portfolios often encounter. The presence of 1 distinct art unit suggests a narrow technological focus for the pending matters within this sector.
The active workload assigned to MCDOWELL, BRIAN E represents the total current engagement with the office. Monitoring the specific tendencies and past allowance rates of this individual is critical, as there are no other pending actions to balance potential difficulties. This arrangement defines the current landscape for Pardes Biosciences Inc.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18461179 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | MCDOWELL, BRIAN E | 71d overdue |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18461179 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | MCDOWELL, BRIAN E | 1624 | — | Non-Final OA | 71d overdue | Pending | Sep 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial